NCT03025477View on ClinicalTrials.gov

Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2032

Conditions
Ovarian Cancer, Epithelial
Interventions
DRUG

CC0 - Carboplatin (IV) - Paclitaxel (IV)

(6 cycles)

DRUG

CC0 - Cisplatin (IP) - Epirubicin (IV)

(6 cycles)

DRUG

CC>0 - Carboplatin (IV)- Paclitaxel (IV)

"* carboplatin (IV) - paclitaxel (IV) (3 cycles)~* Interval surgery~* Carboplatin (IV) - paclitaxel (IV) (3 cycles)"

DRUG

CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)

"* Cisplatin (IV) - Epirubicin (IV) (3 cycles)~* Interval surgery :~ * if CC0: Cisplatin (IP) - Epirubicin (IV) (3 cycles)~ * if CC\>0 Cisplatin (IV)- Epirubicin (IV) (3 cycles)"

Trial Locations (7)

Unknown

RECRUITING

Centre Georges François Leclerc, Dijon

RECRUITING

Institut Hospitalier Franco-Britannique, Levallois-Perret

RECRUITING

Groupe Hospitalier Diaconesses Croix Saint Simon, Paris

RECRUITING

Hôpital Saint Antoine, Paris

RECRUITING

Hôpital Poissy Saint Germain, Poissy

RECRUITING

CHU Poitiers, Poitiers

RECRUITING

Centre Hospitalier Senlis, Senlis

All Listed Sponsors
collaborator

GERCOR - Multidisciplinary Oncology Cooperative Group

OTHER

lead

Groupe Hospitalier Diaconesses Croix Saint-Simon

OTHER